Protocol: Model: Prostate Cancer Screening in general and high-risk population: updates

In November 2023, SCHARR was commissioned by the UK NSC to reassess the cost-effectiveness of prostate cancer screening for men at both average and high risk. The NSC sought strategic health economics support to advance its goal of reducing prostate cancer mortality by improving diagnosis, treatment, and prevention pathways. In response, SCHARR proposed developing a health economics microsimulation model to inform strategic decision-making by the UK NSC. This work builds on SCHARR’s extensive experience with cancer modelling and adapts previous microsimulation frameworks to capture the natural history of prostate cancer. The model was designed to generate policy-relevant evidence and support prioritisation of future research in prostate cancer screening.